AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...

The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S . Shareholders who purchased shares of NVO ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...

LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Novo Nordisk A/S is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obesity treatment, ...

A child in West Texas has died of measles, state health officials said on Wednesday (February 26), the first reported U.S.

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

CASE DETAILS: According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial, "a 68-week efficacy and safety trial ...